053950 — Kyung Nam Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Kyung Nam Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	64,623	59,000	59,303	60,792	55,944
Cost of Revenue
Gross Profit	21,075	16,394	19,298	17,225	15,146
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	71,573	64,901	63,748	61,416	63,349
Operating Profit	-6,949	-5,900	-4,445	-624	-7,405
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-3,299	-7,395	-8,592	-3,220	-8,662
Provision for Income Taxes
Net Income After Taxes	-3,209	-7,828	-9,570	-4,082	-9,007
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-3,413	-7,828	-20,997	10,076	-9,007
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-3,413	-7,828	-20,997	10,076	-9,007
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-135	-163	-193	-88.3	-68.1
Dividends per Share